BenevolentAI Slashes Jobs And Drug Programs
180 Staff To Leave
Executive Summary
The UK firm, which uses artificial intelligence to discover and develop drugs, is hoping to save £45m by halving its workforce and trimming its pipeline.
You may also be interested in...
Verge Builds Out Big Pharma AI Partnerships With AstraZeneca Deal
Deal Snapshot: Two years into a three-year partnership with Lilly, Verge announced another deal, with AstraZeneca’s Alexion, just months after acquiring bragging rights with early clinical data for an AI-discovered product candidate.
BenevolentAI Goes Public In Europe’s Largest SPAC
The UK computational medicines specialist is listing on the Euronext Amsterdam after linking up with healthcare-focused special purpose acquisition corporation Odyssey which is advised by former Sanofi CEO Olivier Brandicourt.
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.